This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia (NCT05355402), a randomized phase 2 study. The primary outcome is Percent Change From Baseline in Fasting TG at Month 6.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT05355402 |
| Phase | Phase 2 |
| Condition | Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Enrollment | 154 |
| Arms in the primary outcome | 3 |
| Lead sponsor | Ionis Pharmaceuticals, Inc. |
| Results posted | Yes |
2. Clinical Question
Population
Adults with hypertriglyceridemia and atherosclerotic cardiovascular disease, either established or at increased risk, and/or severe hypertriglyceridemia. The primary analysis population comprised randomized participants who received any amount of study drug.
Intervention
Olezarsen, administered as a single subcutaneous injection once every 4 weeks for a 53 weeks treatment period. The posted arms were olezarsen 50 mg and olezarsen 80 mg.
Comparator
Olezarsen-matching placebo, administered as a single subcutaneous injection once every 4 weeks for a 53 weeks treatment period.
Primary question
What was the percent change from baseline in fasting triglycerides at Month 6 in each randomized group, and how did the olezarsen groups compare with placebo?
The question is about a continuous laboratory measure: fasting triglyceride levels expressed as percent change from baseline. The primary comparison focuses on the adjusted group differences, rather than only asking whether each group changed from its own starting level. That distinction matters because placebo participants also had a change in the posted results.
The registry describes other objectives that included the proportion of participants reaching fasting triglyceride thresholds and changes in several lipid and apolipoprotein measures. Those outcomes add context about the range of measured lipid results, but they are not substitutes for the declared primary endpoint. The record also posts a threshold outcome among participants with baseline triglycerides below 500 mg/dL. That is a defined subset outcome, not a result for every participant in the primary analysis.
The clinical question and the statistical question are narrower than whether olezarsen alters health outcomes. The primary endpoint measures a laboratory change at Month 6. The registry record does not report a primary endpoint based on cardiovascular events, symptoms, or mortality. Consequently, the posted primary result describes the laboratory endpoint and its uncertainty; it does not by itself answer questions about those other outcomes.
3. Trial Design
The study is identified as NCT05355402 and is described as a randomized, double-blind, placebo-controlled, phase 2b study. Its allocation model was parallel, with quadruple masking recorded. The registry lists an enrollment of 154 and a completed study status. The study started on 2022-05-09, and primary completion was recorded as 2023-03-22.
Three arms appear in the primary results: placebo, olezarsen 50 mg, and olezarsen 80 mg. The placebo group had 39 participants in the primary analysis; the 50 mg group had 58, and the 80 mg group had 57. The treatment descriptions specify a single subcutaneous injection once every 4 weeks during a 53 weeks treatment period. The record describes the placebo as matching olezarsen.
Randomization is intended, in general, to make treatment groups comparable in expectation at the start of a trial, while masking is intended to limit the influence of treatment knowledge on participant care, outcome assessment, or other trial processes. The registry’s labels describe the design, but the detailed procedures used to generate allocation, maintain masking, and assess its success are not reported in the registry record.
The primary analysis used a full analysis set defined as randomized participants who received any amount of study drug. This is the population specified for the reported primary endpoint; it is not necessarily the same as everyone enrolled. The record does not report a separate account of exclusions between enrollment, randomization, treatment receipt, and each analysis. Nor does it report detailed adherence or discontinuation information in the registry record for this summary. Those details would help readers judge how the analyzed population relates to the planned trial population.
A parallel comparison keeps participants in their assigned group rather than describing a crossover. The record reports placebo comparisons for each olezarsen dose. Whether additional design features, such as stratification factors or prespecified covariate choices, were used is not reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: A total of 154 participants were enrolled in the study. All Participants were randomized in 1:1 ratio in two cohorts to receive either 50 mg, or 80 mg, and each cohort was further randomly assigned in a 3:1 ratio to receive olezarsen or olezarsen-matching placebo.
Overall Study
| Stage | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|
| STARTED | 39 | 58 | 57 |
| COMPLETED | 38 | 51 | 52 |
| NOT COMPLETED | 1 | 7 | 5 |
Analysis population for the primary outcome, as defined in the registry: FAS included all participants who were randomized and received any amount of study drug (olezarsen or placebo).
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Population: Full analysis set (FAS) included all participants who were randomized and received any amount of study drug (olezarsen or placebo) and who have at least one post-baseline TG assessment.
| Characteristic | Unit | Placebo | Olezarsen 50 mg | Olezarsen 80 mg | Total |
|---|---|---|---|---|---|
| Participants analysed | 39 | 58 | 57 | 154 | |
| Age, Continuous | years | 63.3 (SD 9.52) | 62.3 (SD 10.15) | 60.4 (SD 10.77) | 61.8 (SD 10.24) |
| Sex: Female, Male: Female | Participants | 24 | 24 | 17 | 65 |
| Sex: Female, Male: Male | Participants | 15 | 34 | 40 | 89 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 0 | 1 | 0 | 1 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 5 | 3 | 5 | 13 |
| Race (NIH/OMB): White | Participants | 34 | 54 | 52 | 140 |
| Race (NIH/OMB): More than one race | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 | 0 |
| Fasting Triglycerides (TG) | milligrams/deciliter (mg/dL) | 302.1 (SD 201.91) | 292.1 (SD 183.01) | 315.1 (SD 221.63) | 303.2 (SD 201.7) |
6. Primary Endpoint
The registry lists the primary outcome as Percent Change From Baseline in Fasting TG at Month 6, measured over Baseline, Month 6.
| Element | Registry entry |
|---|---|
| Result type | Least Squares Mean |
| Measure of spread | 95% Confidence Interval |
| Unit | Percent Change |
| Endpoint classification | Continuous Endpoint |
The primary endpoint is percent change from baseline in fasting triglycerides at Month 6. It is a continuous outcome: participants’ fasting triglyceride measurements are used to characterize a change relative to an individually defined baseline, and group results are expressed as least-squares means with 95% confidence intervals. This kind of endpoint is used to describe the magnitude and precision of a laboratory change, rather than simply classifying each participant as having or not having an event.
The registry defines baseline as the average of the pre-dose measurement on Day 1 and all non-missing measurements from the qualification period. If those measurements were all missing, the last non-missing screening measurement was used. Month 6 was defined as the average of Weeks 25 and 27; if one assessment was missing, the non-missing assessment was used. Missing data after the last observed value for participants in the olezarsen arms were imputed using a jump to reference approach.
In general, a continuous endpoint can retain information about the amount of change across the measurement range, while a threshold endpoint compresses that information into categories. A laboratory endpoint can be useful for testing whether groups differ on the measured quantity over a defined follow-up period. It does not, on its own, establish a change in symptoms, clinical events, or overall health. The registry record does not report a clinical outcome as the primary endpoint.
The endpoint’s definition and handling of missing measurements are important to interpretation: the result is tied to the specified baseline and Month 6 construction, and to the stated imputation approach. The registry record does not report the full analytic specification beyond the details posted with this outcome.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The primary group estimates were a least-squares mean percent change of -7.77 for placebo, -57.05 for olezarsen 50 mg, and -60.92 for olezarsen 80 mg. The corresponding 95% confidence intervals were -15.34 to -0.21 for placebo, -63.19 to -50.92 for 50 mg, and -67.11 to -54.73 for 80 mg. These estimates describe the groups’ adjusted mean changes from baseline at Month 6. They are not individual participant responses, and a group average does not indicate that every participant experienced the same change.
The registry reports ANCOVA comparisons against placebo. The least-squares mean difference was -49.28 for 50 mg versus placebo, with a 95% confidence interval from -59.02 to -39.54 and p < 0.001. For 80 mg versus placebo, the reported difference was -53.15, with a 95% confidence interval from -62.92 to -43.38 and p < 0.001. On the endpoint’s percent-change scale, the negative differences indicate lower estimated percent change in the olezarsen groups than in placebo. Both confidence intervals lie below zero, the value representing no group difference on this scale.
A confidence interval gives a range of values reasonably compatible with the data under the analysis assumptions. In general, narrower intervals indicate greater precision, and wider intervals indicate less precision. These intervals convey uncertainty around the estimated group differences; they should not be read as a range containing every participant’s outcome. The reported p-values quantify evidence against a no-difference statistical null under the fitted analysis, but do not measure the size or clinical importance of an effect.
The two active-dose point estimates are both more negative than the placebo estimate. The posted 80 mg estimate is more negative than the posted 50 mg estimate, but the registry’s reported comparisons test each dose against placebo. A direct statistical comparison between the two olezarsen doses is not reported in the registry record. Therefore, the primary results support reading each dose-versus-placebo comparison on its own, not a claim that one dose is statistically superior to the other.
These results concern fasting triglyceride percent change at Month 6 in the defined analysis population, using the stated baseline construction and missing-data approach. They do not establish the size or duration of any change beyond the measured endpoint and follow-up specified in the record. Nor do they establish effects on cardiovascular events or other patient outcomes, which are not the primary endpoint.
9. Statistical Methods Explained
What does a least-squares mean represent?
The primary results are least-squares means, often called adjusted means. In general, these are model-based estimates of group averages after accounting for the terms included in the statistical model. They can differ from simple arithmetic averages when the model adjusts for covariates or other design features. The registry identifies ANCOVA for the pairwise primary comparisons, but the complete list of model terms and covariates is not reported in the registry record.
The registry reports the group estimates as -7.77 for placebo, -57.05 for olezarsen 50 mg, and -60.92 for olezarsen 80 mg. It also reports adjusted differences against placebo. A difference is useful because it directly expresses the contrast of interest between randomized groups. The posted differences are -49.28 for 50 mg versus placebo and -53.15 for 80 mg versus placebo. The interpretation remains tied to the endpoint’s percent-change scale.
How should the confidence intervals be read?
Each primary group estimate and treatment comparison is accompanied by a 95% confidence interval. In general, a confidence interval reflects the precision of an estimate under the model and sampling assumptions. It does not describe the spread of individual participant outcomes, and it does not assign a probability that a fixed true value lies inside the particular interval after the data have been observed.
For the adjusted comparisons, the registry reports intervals of -59.02 to -39.54 for 50 mg versus placebo and -62.92 to -43.38 for 80 mg versus placebo. Both intervals are on the negative side of zero. Zero represents no difference in the modeled contrast. The interval bounds are important alongside the point estimates because they show a range of plausible contrast values under the analysis, not merely whether a p-value crosses a threshold.
What does ANCOVA contribute?
ANCOVA is a general method for comparing group means while adjusting for selected covariates. Adjustment can improve precision or account for prespecified features associated with the outcome, depending on the design and model. Randomization remains the basis for the treatment-group comparison; covariate adjustment does not change the need to examine the analysis population, outcome definition, and missing-data handling. The registry names ANCOVA and reports least-squares mean differences, but detailed model specification beyond those details is not reported in the registry record.
Why does the missing-data method matter?
The primary outcome definition uses averaging rules for baseline and Month 6, including use of a single available Month 6 assessment if the other is missing. For olezarsen participants with missing data after their last observed value, the record states that values were imputed using jump to reference, or J2R. In general, J2R imputes subsequent outcomes under an assumption that the treatment group’s post-missing trajectory behaves like the reference group. This is an assumption-based approach, not a direct observation of the missing measurements. The registry record does not report enough detail to assess all implementation choices or alternative missing-data analyses.
Missing-data assumptions can affect estimates when outcomes are unavailable, particularly if missingness is related to participants’ unobserved outcomes. In general, sensitivity analyses test whether conclusions are robust to alternative plausible assumptions. Whether such analyses were conducted, and what they showed, is not reported in the registry record. Readers should therefore interpret the primary estimate as conditional on the stated endpoint construction and imputation approach.
How should the p-values be understood?
The registry reports p < 0.001 for each primary dose-versus-placebo comparison. In general, a p-value describes how surprising data at least as incompatible with a statistical null would be if that null and the analysis assumptions held. It is not the probability that the null is true, and it does not quantify the probability that the finding is due to chance. Effect estimates and confidence intervals provide information about magnitude and precision that a p-value alone cannot supply.
The registry labels these analyses as superiority comparisons. The p-values and intervals belong to the reported comparisons, but the overall implications depend on the full analysis plan, including any handling of multiple comparisons. Whether a multiplicity adjustment was prespecified or used is not reported in the registry record. The stated p-values should not be treated as proof of a broader claim beyond the specific modeled endpoint and comparisons.
What can the planning illustrations tell readers?
Separate calculations based on posted threshold-outcome summaries are planning illustrations, not observed power and not a reconstruction of the trial’s design. They use an observed effect or a stated fraction of it, equal allocation, a two-sided significance level of 0.05, and a normal approximation. For example, the planning rows distinguish planning for 100%, 75%, or 50% of the observed effect and give participants per arm for 80% power and participants per arm for 90% power. In general, smaller target effects require larger planned sample sizes when other assumptions are held fixed.
These illustrations are especially sensitive to the observed event proportions and should not be interpreted as a sample-size justification for this study. The trial’s own sample-size assumptions and justification are not reported in the registry record. A planning calculation based on an observed result cannot show that the original study had a particular probability of detecting an effect.
10. Analyses Reported by the Sponsor
| Method | Estimate | 95% CI | P-value |
|---|---|---|---|
| ANCOVA | Least Squares (LS) Mean Difference -49.28 | -59.02 to -39.54 | < 0.001 |
| ANCOVA | LS Mean Difference -53.15 | -62.92 to -43.38 | < 0.001 |
The primary results include sponsor-reported ANCOVA comparisons as well as the group least-squares means. The sponsor’s reported estimate for olezarsen 50 mg versus placebo is -49.28, with a 95% confidence interval from -59.02 to -39.54 and p < 0.001. For olezarsen 80 mg versus placebo, the estimate is -53.15, with a 95% confidence interval from -62.92 to -43.38 and p < 0.001.
Simple recalculations from posted summary statistics are not included for this continuous endpoint. In general, a recalculation from group-level summaries cannot reproduce an adjusted ANCOVA result because the model may use participant-level information and covariate adjustment not recoverable from those summaries. The registry-reported analysis is therefore the relevant source for the primary inferential comparisons. There is no discrepancy flagged between a recalculation and the reported analysis.
The sponsor’s analysis supplies the modeled treatment contrasts, their confidence intervals, and p-values. These are estimates under the registry-reported method, not a guarantee that the same values would appear under every reasonable model or missing-data assumption. The record does not report sufficient model detail to independently assess all analytic choices. Readers can interpret the sponsor’s results as evidence about the specific Month 6 fasting triglyceride endpoint, while keeping the stated population and imputation approach in view.
11. Multiplicity, Missing Data and Analysis Populations
Multiplicity arises when an analysis tests more than one hypothesis, such as several doses, time points, or outcomes. In general, the more tests conducted, the greater the chance that at least one result appears statistically notable by chance if all null hypotheses are true. Prespecified procedures can control the overall error rate or define a hierarchy for interpreting tests. Whether the study used a multiplicity adjustment, a hierarchy, or another testing strategy is not reported in the registry record.
The primary endpoint has two reported comparisons, one for each olezarsen dose against placebo. Both are reported with p < 0.001 and 95% confidence intervals. The record labels the comparisons as superiority analyses, but that does not by itself specify how multiplicity was handled across dose comparisons or across the wider set of endpoints. The secondary results include multiple outcomes and time points, so their p-values should be interpreted cautiously in the absence of a reported testing plan.
The primary analysis population is defined as randomized participants who received any amount of study drug. This definition is explicit, but details about the numbers excluded from analysis, reasons for exclusion, and outcome availability by group are not reported in the registry record. The enrolled total is 154, while the primary analysis group counts are 39 for placebo, 58 for olezarsen 50 mg, and 57 for olezarsen 80 mg. The registry does not provide a full participant flow account in the information used for this summary.
Missing endpoint data were handled in part through the Month 6 averaging rule and J2R imputation after the last observed value for olezarsen participants. In general, imputation replaces missing observations with values generated under a stated model or assumption; it does not recover known outcomes. The record does not report the amount or reasons for missing data, details of imputation implementation, or sensitivity analyses using alternative assumptions. These omissions limit assessment of how dependent the estimates are on missing-data choices.
The trial’s own sample-size justification, interim-analysis plan, and full statistical analysis plan are not reported in the registry record. Planning illustrations based on observed secondary effects are separate calculations and cannot fill those gaps or be interpreted as observed power.
12. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Placebo | 2 | 39 | 5.1% |
| Olezarsen 50 mg | 6 | 58 | 10.3% |
| Olezarsen 80 mg | 8 | 57 | 14.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Placebo | 0 of 39 |
| Olezarsen 50 mg | 1 of 58 |
| Olezarsen 80 mg | 0 of 57 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Placebo | 22 of 39 |
| Olezarsen 50 mg | 32 of 58 |
| Olezarsen 80 mg | 24 of 57 |
Most frequent serious adverse event terms
| Event term | Organ system | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|---|
| Sepsis | Infections and infestations | 0 of 39 | 1 of 58 | 1 of 57 |
| Tibia fracture | Injury, poisoning and procedural complications | 1 of 39 | 0 of 58 | 1 of 57 |
| Acute myocardial infarction | Cardiac disorders | 0 of 39 | 1 of 58 | 0 of 57 |
| Angina pectoris | Cardiac disorders | 0 of 39 | 0 of 58 | 1 of 57 |
| Atrial fibrillation | Cardiac disorders | 0 of 39 | 1 of 58 | 0 of 57 |
| Coronary artery disease | Cardiac disorders | 0 of 39 | 1 of 58 | 0 of 57 |
| Left ventricular failure | Cardiac disorders | 0 of 39 | 1 of 58 | 0 of 57 |
| Tachycardia | Cardiac disorders | 0 of 39 | 0 of 58 | 1 of 57 |
| Pancreatitis acute | Gastrointestinal disorders | 0 of 39 | 1 of 58 | 0 of 57 |
| Small intestinal obstruction | Gastrointestinal disorders | 0 of 39 | 0 of 58 | 1 of 57 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Placebo | Olezarsen 50 mg | Olezarsen 80 mg |
|---|---|---|---|---|
| Urinary tract infection | Infections and infestations | 6 of 39 | 6 of 58 | 3 of 57 |
| COVID-19 | Infections and infestations | 2 of 39 | 5 of 58 | 4 of 57 |
| Injection site erythema | General disorders | 0 of 39 | 8 of 58 | 2 of 57 |
| Diabetes mellitus | Metabolism and nutrition disorders | 1 of 39 | 4 of 58 | 4 of 57 |
| Fatigue | General disorders | 1 of 39 | 6 of 58 | 1 of 57 |
| Nasopharyngitis | Infections and infestations | 2 of 39 | 2 of 58 | 3 of 57 |
| Back pain | Musculoskeletal and connective tissue disorders | 1 of 39 | 5 of 58 | 1 of 57 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 2 of 39 | 5 of 58 | 0 of 57 |
| Bronchitis | Infections and infestations | 3 of 39 | 3 of 58 | 0 of 57 |
| Sinusitis | Infections and infestations | 4 of 39 | 1 of 58 | 1 of 57 |
Serious events with the highest arm-level rate: tibia fracture (2.6%), head injury (2.6%), ligament sprain (2.6%), endometrial cancer stage i (2.6%), syncope (2.6%).
The posted serious adverse event counts were 2 of 39 participants in the placebo group, 6 of 58 in the olezarsen 50 mg group, and 8 of 57 in the olezarsen 80 mg group. Deaths were 0, 1, and 0, respectively. These are counts of participants with serious adverse events and deaths as posted, not a complete description of every event, its timing, duration, or relationship to study treatment.
The record also lists serious adverse event terms with reported percentages: tibia fracture, head injury, ligament sprain, endometrial cancer stage I, and syncope each at 2.6%, and angina pectoris at 1.8%. These terms describe reported events; the registry information does not establish that treatment caused them. The posted figures alone cannot distinguish treatment-related events from events arising for other reasons.
In general, safety counts from a trial should be interpreted in light of the number of participants, follow-up, event definitions, and the way events were collected and coded. The record’s group counts permit a descriptive comparison, but do not provide enough detail to establish comparative risk or causality. They should be read as a safety description from this study, not as medical advice or a prediction for an individual.
13. What the Result Does, and Does Not, Mean
The primary finding is a difference between randomized groups in the reported Month 6 fasting triglyceride percent-change endpoint. The registry’s adjusted comparisons estimate a -49.28 difference for olezarsen 50 mg versus placebo and a -53.15 difference for olezarsen 80 mg versus placebo; both reported 95% confidence intervals exclude zero and both p-values are below < 0.001. These statistics describe the measured endpoint under the specified analysis, population, and missing-data approach.
The estimates do not mean that every participant experienced the group average change. They do not describe how an individual will respond, and a confidence interval for a group contrast is not an interval for individual outcomes. Nor does a small p-value measure the clinical importance of the difference. Clinical meaning depends on context beyond the statistical evidence, and the registry record does not establish a threshold for interpreting the importance of this laboratory change.
The outcome is a fasting triglyceride measurement, not a cardiovascular event or a measure of symptoms, quality of life, or survival. The primary result therefore does not answer whether cardiovascular outcomes changed. The record lists other lipid measures and safety outcomes, but the primary finding should not be expanded into claims about outcomes that are not reported as the primary endpoint.
The study was randomized, masked, and placebo-controlled, which supports a structured comparison between assigned groups. However, interpretation still depends on how participants were analyzed, the completeness of follow-up, model choices, missing-data assumptions, and any multiplicity strategy. Some of these details are not reported in the registry record. The posted result is a precise statistical summary of the reported analysis, not a complete account of every analytic uncertainty.
The results also should not be generalized automatically to populations or settings beyond the enrolled study population. The record describes adults with hypertriglyceridemia and cardiovascular disease or severe hypertriglyceridemia; it does not provide evidence about all populations or clinical circumstances. The statistical conclusion remains restricted to the population and laboratory endpoint described in the registry.
14. Why This Trial Matters Statistically
This trial is statistically informative because it reports a continuous primary endpoint, group-level estimates, confidence intervals, and adjusted comparisons for two randomized dose groups against placebo. Readers can distinguish the size of the estimated contrasts from their precision and can see that the placebo group also had a measured change. This is more informative than relying on a single p-value or on within-group changes alone.
The outcome definition also makes clear that endpoint construction is part of the estimand being interpreted. Baseline and Month 6 are based on specified averaging rules, and the record states how a single missing Month 6 measurement is handled. It also specifies J2R imputation after the last observed value for participants in the olezarsen arms. Making those rules visible matters because different missing-data assumptions can lead to different estimates.
The range of secondary endpoints provides a wider laboratory context, while the threshold outcomes illustrate how continuous data can be recast as attainment of a cutoff. These are not interchangeable questions. The threshold analysis is based on a specified baseline subgroup and cutoff, while the primary analysis uses continuous percent change. Statistical interpretation benefits from keeping their estimands distinct and avoiding the impression that multiple related outcomes are independent confirmations.
The study also illustrates why a large-looking contrast and a small p-value do not remove the need to ask about multiplicity, missingness, analysis populations, and model details. The registry does not report several elements of the full statistical plan, including multiplicity handling and the trial’s sample-size justification. Recognizing those gaps supports a more calibrated reading: the posted analysis gives evidence about a defined laboratory endpoint, while some broader inferential questions remain open.
15. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The registry record does not report the full ANCOVA specification, including all covariates and model diagnostics. Without that information, readers cannot independently reproduce the adjusted least-squares estimates or assess the impact of alternative modeling choices. The reported primary comparisons remain the appropriate description of the sponsor’s analysis, but their interpretation depends on details not available in the record.
Information about participant flow, adherence, discontinuations, and the quantity and reasons for missing outcomes is not reported in the registry record. The primary population is defined, and the missing-data method is named, but these registry entries alone do not show how many observations were imputed or whether missingness differed across groups. The record also does not report sensitivity analyses that would show how conclusions change under different missing-data assumptions.
The study includes multiple doses, time points, and secondary outcomes. Whether the statistical plan controlled multiplicity is not reported in the registry record. This is relevant to interpretation of secondary findings and potentially to the family of primary comparisons. The registry also does not report the trial’s own sample-size justification or interim-analysis approach, so neither can be assessed from the posted information.
The primary outcome is a laboratory measure assessed at Month 6. The record does not make this endpoint a substitute for clinical outcomes, and the primary result does not establish the effect on cardiovascular events or other outcomes not designated as primary. The posted adverse event counts are descriptive and do not report enough detail about timing or attribution to establish causality.
Finally, the trial’s stated population limits direct generalization. The results pertain to adults with the conditions described in the record and the treatment regimens studied. The registry information does not by itself establish that estimates apply to populations outside that description, to other follow-up periods, or to different treatment settings.
16. Related Tutorials
17. Related Statistical Calculators
18. Sources
- ClinicalTrials.gov: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia — NCT05355402.
- Registry record last updated 2026-04-23; status last verified 2026-04.
- Results first posted 2026-04-23.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
19. Record Summary
NCT05355402 is a completed, randomized, double-blind, placebo-controlled phase 2b parallel study with quadruple masking recorded. Enrollment was 154. Participants were assigned to placebo, olezarsen 50 mg, or olezarsen 80 mg, administered once every 4 weeks for a 53 weeks treatment period.
The primary endpoint was percent change from baseline in fasting triglycerides at Month 6, analyzed in randomized participants who received any amount of study drug. The registry reports ANCOVA comparisons against placebo: -49.28 for 50 mg and -53.15 for 80 mg, each with a 95% confidence interval excluding zero and p < 0.001.
The record also posts secondary lipid outcomes, threshold attainment results, and adverse event counts. Multiplicity handling, the full statistical analysis plan, and the trial’s sample-size justification are not reported in the registry record. The primary result is specific to the defined laboratory endpoint and analysis.